Scientists test 'Goldilocks' drug dose to make transplants safer

This study tested whether a personalized dose of a drug called ATG works better than a standard fixed dose for patients receiving a stem cell transplant from a half-matched donor. The goal was to find the dose that best prevents a dangerous complication where the donor cells attack the patient's body (graft-versus-host disease), while also keeping the risk of serious viral infections low. Researchers compared the two dosing approaches in 204 patients to see which led to better overall outcomes.